Aquestive Therapeutics, Inc. Gain (Loss) on Extinguishment of Debt
Aquestive Therapeutics, Inc. (AQST) reported Gain (Loss) on Extinguishment of Debt of -$11.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-11
- Aquestive Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was -$11.68M.
- Aquestive Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- Aquestive Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- Aquestive Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- Aquestive Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- Aquestive Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was -$1.38M.
- Aquestive Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
- Aquestive Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2021 was -$13.82M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 3 month as first filed | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$11.68M 10-Q · filed 2026-08-11 | -$11.68M 10-Q · filed 2026-08-11 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | $0.00 10-K · filed 2025-03-05 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | -$1.03M derived: sum of 4 quarters · filed 2025-03-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | -$1.03M derived: sum of 3 quarters · filed 2025-03-05 | -$1.03M derived: sum of 4 quarters · filed 2025-03-05 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | -$1.03M derived: sum of 2 quarters · filed 2025-03-05 | -$1.03M derived: sum of 3 quarters · filed 2025-03-05 | -$1.03M derived: sum of 4 quarters · filed 2025-03-05 | |
| 2023-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$1.03M derived: sum of 2 quarters · filed 2025-03-05 | -$1.03M derived: sum of 3 quarters · filed 2025-03-05 | -$1.38M 10-K · filed 2025-03-05 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | -$353.00K 10-Q · filed 2024-11-04 | -$353.00K derived: sum of 4 quarters · filed 2024-11-04 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | -$353.00K 10-Q · filed 2024-08-06 | -$353.00K derived: sum of 3 quarters · filed 2024-08-06 | -$353.00K derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | -$353.00K 10-Q · filed 2024-05-07 | -$353.00K derived: sum of 2 quarters · filed 2024-05-07 | -$353.00K derived: sum of 3 quarters · filed 2024-05-07 | -$353.00K derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 10-K · filed 2024-03-05 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | -$13.82M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | -$13.82M derived: sum of 3 quarters · filed 2023-08-07 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | -$13.82M derived: sum of 2 quarters · filed 2023-05-02 | |||
| 2021-12-31 | -$13.82M 10-Q · filed 2022-11-01 | $13.82M 10-Q · filed 2022-05-04 | -$13.82M 10-K · filed 2023-03-31 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $0.00 derived: sum of 2 quarters · filed 2022-03-08 | $0.00 10-K · filed 2022-03-08 | ||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$4.90M derived: sum of 2 quarters · filed 2021-03-09 | -$4.90M 10-K · filed 2021-03-09 | ||
| 2019-09-30 | -$4.90M 10-Q · filed 2020-11-04 | -$4.90M 10-Q · filed 2020-11-04 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |